Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database
Epilepsy is a common neurologic disorder in the United States, with an estimated prevalence of 3.4 million cases, and approximately 150,000 new cases of epilepsy are diagnosed annually.
The Importance of Clinical and Economic Support Systems for Caregivers
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly
Melanoma is the fifth most common malignancy among men and the sixth most common malignancy among women in the United States. The American Cancer Society estimated that in 2018, 91,270 new cases of invasive melanoma will be diagnosed in the United States, and the disease will result in approximately 9320 deaths.
It’s About the Total Cost of Care
Computed Tomography Colonography Less Costly Than Colonoscopy for Colorectal Cancer Screening of Commercially Insured Patients
Tia Goss Sawhney, DrPH, FSA, MAAA, Bruce S. Pyenson, FSA, MAAA, David Rotter, PhD, Michele Berrios, Judy Yee, MD
In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among men and women and the second leading cause of death from cancer.1 The majority of cases of CRC can be prevented by the detection and removal of noncancerous adenomatous polyps (adenomas).
Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation
Derek Ems, MPH, Sharanya Murty, PhD, Bryan Loy, MD, Judith Gallagher, MBA, Laura E. Happe, PharmD, MPH, Teresa L. Rogstad, MPH, Debra Finnel, Jimmy D. Fernandez, MD, MBA
Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
Ivar S. Jensen, MBA, Elizabeth Wu, MPH, Naomi C. Sacks, PhD, Philip L. Cyr, MPH, Karen C. Chung, PharmD, MS
Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies
Vincent J. Willey, PharmD, Sheldon Kong, PhD, Bingcao Wu, MS, Amit Raval, PhD, Todd Hobbs, MD, Andrea Windsheimer, PharmD, Gaurav Deshpande, MS, PhD, Ozgur Tunceli, PhD, Brian Sakurada, PharmD, Jonathan R. Bouchard, MS, RPh
Diabetes mellitus imposes a substantial clinical and economic burden on the US healthcare system. National estimates reported in 2017 indicate that 9.4% of the US population, or 30.3 million Americans, have diabetes; however, only 23.1 million have actually been diagnosed with the disease, which means that 7.2 million people (or 23.8% of those with diabetes) were undiagnosed.
The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women
Christine Ferro, CHFP, Bruce S. Pyenson, FSA, MAAA, Jocelyn Lau, MPH, Mona Kelkar, MBA, Nancy Phillips, MD, Chi-Wei Lu, PhD, Percy Yeung, PhD, Gloria Bachmann, MD
During the later weeks of pregnancy, pregnant women are often concerned with suspected leakage of amniotic fluid, which, whether preterm or at term, requires evaluation and medical intervention. The rupture of membranes occurs in an estimated 8% to 10% of full-term pregnancies.
Interventions to Reduce Avoidable Pregnancy-Related Emergency Department Visits
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Inflammatory bowel disease (IBD) is a chronic, lifelong disorder of the gastrointestinal tract associated with an unpredictable relapsing and remitting disease course. Ulcerative colitis (UC) and Crohn’s disease (CD) are 2 common phenotypes of IBD. Patients with IBD often have considerable symptom burden despite appropriate treatment, and IBD frequently leads to debilitating complications that may require hospitalization, surgery, and/or the escalation of therapy.
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy
Machaon M.K. Bonafede, PhD, MPH, Donna McMorrow, BS, Clare Proudfoot, PhD, Shraddha Shinde, MS, MBA, Andreas Kuznik, PhD, Chieh-I Chen, MPH
This retrospective analysis is based on inpatient medical claims, outpatient medical claims, and pharmacy claims from the Truven Health MarketScan Commercial Database. The database includes claims for approximately 35 million employees and their dependents in fee-for-service and managed care health plans.
Page 1 of 13
Results 1 - 10 of 124
Results 1 - 10 of 124